Kyverna Therapeutics, Inc. shareholders approved Ratification of appointment of BDO USA, P.C. as independent registered public accounting firm at the 2026-05-27 meeting.
“Votes For Votes Against Abstentions 43,830,300 80,223 76,484”
Kyverna Therapeutics, Inc. — fact timeline
Source-grounded facts extracted from Kyverna Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Kyverna Therapeutics, Inc. shareholders approved Election of two Class II directors at the 2026-05-27 meeting.
“Director Nominee Votes For Votes Withheld Broker Non-Votes Ian Clark 31,505,902 3,255,231 9,225,874 Christi Shaw 34,528,865 232,268 9,225,874”
Gregory Martini was appointed as Chief Financial Officer at Kyverna Therapeutics, Inc..
“On May 14, 2026, the Board of Directors (the “Board”) of Kyverna Therapeutics, Inc. (the “Company”) appointed Gregory Martini as the Company’s Chief Financial Officer, effective May 18, 2026 (the “Effective Date”).”
Kyverna Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.
“On May 12, 2026, Kyverna Therapeutics, Inc. (the “Company”) issued a press release providing a business update and reporting financial results for the quarter ended March 31, 2026.”
Kyverna Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2025.
“Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results”
Kyverna Therapeutics, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Leerink Partners LLC and Morgan Stanley & Co. LLC valued at approximately $100 million (effective 2025-12-17).
“On December 17, 2025, Kyverna Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Leerink Partners LLC and Morgan Stanley & Co. LLC as the representatives (the “Representatives”) of the several underwriters named therein (the “Underwriters”), relating to the issuance and sale in an underwritten public offering (the “Offering”) of an aggregate of 13,333,333 shares of common stock”
Kyverna Therapeutics, Inc. incurred term loan of up to $150.0 million with Oxford Finance LLC at a floating per annum rate equal to (a) the greater of (i) the 1-Month CME Term S maturing October 1, 2030.
“from time to time party thereto. The Loan and Security Agreement provides a non-dilutive term loan facility (the “Loan Facility”) up to an aggregate principal amount of up to $150.0 million in multiple tranches, subject to certain conditions. The Loan Facility includes an initial tranche of $40.0 million and two additional tranches totaling $60.0 million, subject to”
James Chung resigned as Chief Medical Officer at Kyverna Therapeutics, Inc..
“As previously disclosed, James Chung, M.D., Ph.D., Chief Medical Officer of Kyverna Therapeutics, Inc. (the “Company”), resigned from the Company, to be effective as of November 22, 2024.”
James Chung resigned as Chief Medical Officer at Kyverna Therapeutics, Inc..
“On November 8, 2024, James Chung, M.D., Ph.D., Chief Medical Officer of the Company, resigned from the Company, to be effective as of November 22, 2024.”
Mert Aktar was appointed as Class III director at Kyverna Therapeutics, Inc..
“On October 20, 2024, the board of directors (the "Board") of Kyverna Therapeutics, Inc. (the "Company") appointed Mert Aktar as a Class III director of the Company, effective October 20, 2024.”
Warner Biddle was appointed as Chief Executive Officer and Class III director at Kyverna Therapeutics, Inc..
“appointed Warner Biddle as the Company’s Chief Executive Officer and as a Class III director of the Company, in each case effective September 16, 2024”
Kyverna Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income a net loss of $26.7 million, EPS a net loss per common share of $1.12.
“For the quarter ended March 31, 2024, the company reported a net loss of $26.7 million, or a net loss per common share of $1.12”
Kyverna Therapeutics, Inc. reported the full year ended December 31, 2023 results: net income net loss of $60.4 million, or a net loss per common share of $89.61, EPS net loss per common share of $89.61.
“For the year ended December 31, 2023, the company reported a net loss of $60.4 million, or a net loss per common share of $89.61, compared to a net loss of $28.9 million, or a net loss per common share of $63.43, for the same period in 2022.”
Kyverna Therapeutics, Inc.: Amended and restated certificate of incorporation and bylaws effective upon closing of IPO, including provisions on capital stock, board classification, exclusive forum, and stockholder action by written consent prohibition (effective 2024-02-12).
“On February 12, 2024, Kyverna Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware, and the Certificate of Incorporation and its amended and restated bylaws (the “Bylaws”) became effective in connection with the closing of the initial public offering of shares of the Company’s common stock.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.